Balanced news tone
News Sentiment
LIVN sentiment intelligence
LivaNova PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
News tone and price action are not far from neutral.
76/100 classification confidence.
directly relevant articles
high-authority source matches
-1.3% over one week, +4.0% over four weeks, trend active, and materially above fair value.
LIVN Maintains by Mizuho -- Price Target Raised to $95.00
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
LIVN Maintains by Mizuho -- Price Target Raised to $95.00
Mizuho analyst Anthony Petrone maintained an Outperform rating for LivaNova (LIVN) and raised the price target to $95.00 from $90.00. This reflects confidence in the company's growth, despite GuruFocus indicating LIVN is currently overvalued with a GF Value™ of $62.61 against a c
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 15 Jul 2026 19:40
- Source
- GuruFocus
LivaNova PLC (LIVN) Shares Fall 4.7% -- GF Value Says Still Over
- Tone
- Negative 22/100
- Event
- Market update
- Published
- 14 Jul 2026 23:55
- Source
- GuruFocus
Reflecting On Medical Devices & Supplies - Specialty Stocks’ Q1 Earnings: Integer Holdings (NYSE:ITGR)
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 14 Jul 2026 18:07
- Source
- Market source
LivaNova PLC (LIVN) Shares Fall 4.7% -- GF Value Says Still Overvalued
LivaNova PLC (LIVN) shares fell 4.7% to $79.13, yet GuruFocus's GF Value still assesses the stock as "Modestly Overvalued" with an estimated intrinsic value of $62.60. Despite a current P/E ratio lower than its historical median, insider selling of $0.2 million with no buying act
- Tone
- Negative 36/100
- Event
- Market update
- Published
- 14 Jul 2026 18:43
- Source
- GuruFocus
LivaNova PLC (LIVN) hit a 52 week high, can the run continue?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 15:45
- Source
- MSN
LivaNova appoints Anne Liddy as chief legal officer
LivaNova has announced the appointment of Anne Liddy as the new chief legal officer. Liddy brings experience from her previous role as global legal head for the cardiovascular, renal, and medical products group at Baxter International, and has held positions at Hillrom and Abbott
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 13:40
- Source
- MSN
Enterprise value to EBIT forward of LivaNova Plc – SWB:LIA
This article provides financial information for LivaNova Plc (SWB:LIA), specifically focusing on its enterprise value to EBIT forward. The content is presented within the context of TradingView's platform, offering financial data and market insights for the Stuttgart Stock Exchan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 03:13
- Source
- TradingView
Price to earnings forward of LivaNova Plc – SWB:LIA
This article provides financial information for LivaNova Plc (SWB:LIA), specifically focusing on its Price to Earnings Forward metric. The content, presented by TradingView, is part of a larger financial data service, indicating no specific data points but rather a static page fo
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 10 Jul 2026 02:39
- Source
- TradingView
Price to sales forward of LivaNova PLC – NASDAQ:LIVN
This article provides the "Price to sales forward" metric for LivaNova PLC (NASDAQ: LIVN) on TradingView. It indicates that the market is closed and no trades have occurred for this specific metric. The content is presented within the context of TradingView's financial analysis t
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 07:13
- Source
- TradingView
LivaNova PLC balances neuromodulation growth with cardiac surgery challenges
LivaNova PLC focuses on expanding its neuromodulation solutions for neurological disorders while maintaining its core presence in cardiac surgery devices. The company balances investments between these two areas, with neuromodulation offering higher growth potential and cardiac s
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 17:18
- Source
- AD HOC NEWS
(LIVN) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth AI-driven analysis for Livanova Plc (NASDAQ: LIVN), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk he
- Tone
- Positive 82/100
- Event
- Balance sheet
- Published
- 08 Jul 2026 15:06
- Source
- Stock Traders Daily
Price to book forward of LivaNova PLC – NASDAQ:LIVN
This article provides financial data for LivaNova PLC (NASDAQ: LIVN), specifically its price-to-book forward ratio. It is a brief financial snippet from TradingView, offering current valuation metrics for the company.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 17:39
- Source
- TradingView
LivaNova Stock Sinks After Key Sleep Trial Fails
LivaNova PLC's stock is falling after its OSPREY clinical trial for the aura6000 sleep apnea device failed to achieve its primary efficacy goal, leading to the study's discontinuation. This setback eliminates a significant growth opportunity for LivaNova and concerns investors ab
- Tone
- Negative 19/100
- Event
- Market update
- Published
- 07 Jul 2026 17:39
- Source
- TipRanks
Enterprise value to EBITDA forward of LivaNova PLC – NASDAQ:LIVN
This article focuses on the enterprise value to EBITDA forward for LivaNova PLC (NASDAQ: LIVN) as presented on TradingView. It appears to be a financial data snippet from a larger platform, indicating the company's financial metrics under the "Financials" section. The document pr
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 14:11
- Source
- TradingView
LivaNova PLC focuses on neuromodulation and cardiopulmonary solutions as investors track its Nasdaq-listed stock
LivaNova PLC (LIVN) is a global medical technology company listed on Nasdaq, specializing in medical devices for cardiovascular care and neuromodulation therapy. The company's long-term growth is driven by demand for life-saving procedures and chronic disease management, with a f
- Tone
- Positive 65/100
- Event
- Macro sensitivity
- Published
- 07 Jul 2026 12:11
- Source
- AD HOC NEWS
Price to sales forward of LivaNova Plc – LSX:A14156
This article displays the "Price to sales forward" metric for LivaNova Plc (LSX:A14156) on TradingView. It appears to be a financial data snippet from the platform, showing basic company information and navigation to various financial tools and community features.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 08:11
- Source
- TradingView
How LivaNova’s Broad Russell Index Inclusion Will Impact LivaNova (LIVN) Investors
LivaNova PLC (NasdaqGS:LIVN) was recently added to several Russell growth and small-cap indexes, including the Russell 2000 Growth-Defensive Index and Russell 3000 Growth Benchmark. This inclusion is expected to increase the company's visibility among institutional investors but
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 07 Jul 2026 05:10
- Source
- Simply Wall Street
Enterprise value to EBIT forward of LivaNova Plc – DUS:LIA
This article provides financial information for LivaNova Plc (DUS:LIA) including its Enterprise Value to EBIT forward metric. The content appears to be a stub or a section of a larger financial data page from TradingView, displaying various navigation and informational links rela
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Jul 2026 23:41
- Source
- TradingView
LivaNova stock hits 52-week high at 84.3 USD
LivaNova PLC's stock reached a new 52-week high of $84.30, demonstrating an 81% total return over the past year. The company also announced promising data from its PolySync algorithm for sleep apnea and made several strategic leadership appointments and board additions. Investing
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 06 Jul 2026 13:40
- Source
- Investing.com
LivaNova (LIVN) Joins Russell Indexes, Is The Stock Fully Priced?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 07:00
- Source
- simplywall.st
LivaNova Shares Positive 12-Month Results From Obstructive Sleep Apnea Study
LivaNova Plc announced positive 12-month results from its OSPREY randomized controlled trial (RCT) for the aura6000 System, demonstrating the safety and efficacy of proximal hypoglossal nerve stimulation (pHGNS) in treating moderate to severe obstructive sleep apnea (OSA). The st
- Tone
- Positive 92/100
- Event
- Earnings
- Published
- 30 Jun 2026 16:10
- Source
- Medical Product Outsourcing
Livanova stock initiated at Hold by Freedom Capital on growth outlook
- Tone
- Positive 66/100
- Event
- Guidance
- Published
- 30 Jun 2026 07:00
- Source
- Investing.com
LivaNova PLC(NasdaqGS: LIVN) added to Russell Small Cap Comp Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN), a medical technology company specializing in cardiopulmonary and neuromodulation products, has been added to the Russell Small Cap Comp Growth Benchmark. This inclusion was formalized on June 29, 2026, alongside its addition to several other Russell
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 Jun 2026 21:09
- Source
- www.marketscreener.com
LivaNova PLC(NasdaqGS: LIVN) added to Russell 2000 Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN), a medical technology company, has been added to the Russell 2000 Growth Benchmark. The company designs, develops, manufactures, markets, and sells products and therapies across its Cardiopulmonary and Neuromodulation segments. This inclusion highlig
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 29 Jun 2026 10:43
- Source
- www.marketscreener.com
LivaNova PLC(NasdaqGS: LIVN) added to Russell 3000 Growth Benchmark
LivaNova PLC (NasdaqGS: LIVN) was added to the Russell 3000 Growth Benchmark on June 28, 2026. The company is a medical technology firm specializing in cardiopulmonary and neuromodulation products and therapies. LivaNova has also been added to other Russell benchmarks, including
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 29 Jun 2026 04:09
- Source
- www.marketscreener.com
(LIVN) Risk Channels and Responsive Allocation
This article analyzes Livanova Plc (LIVN) using AI models, identifying strong sentiment across all horizons supporting an overweight bias. It provides institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe sig
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 27 Jun 2026 14:10
- Source
- Stock Traders Daily
Livanova PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh
This page provides financial actuals and estimates for Livanova PLC Shs Unsponsored Brazilian Depositary Receipt Repr 0.125 Sh (L2IV34) traded on BMFBOVESPA. Users can explore reported financial data and analyst estimates for income statements, balance sheets, cash flow statement
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 27 Jun 2026 05:39
- Source
- TradingView
LivaNova Plc Actuals & Estimates (NASDAQ:LIVN)
This article provides an overview of LivaNova PLC (NASDAQ: LIVN) stock, including its current price, performance, and analyst forecasts. It details financial actuals and estimates for the company's income statement, balance sheet, and cash flow, alongside answers to frequently as
- Tone
- Positive 66/100
- Event
- Analyst action
- Published
- 26 Jun 2026 20:39
- Source
- TradingView
LIVN Forecast — Price Target — Prediction for 2027
This article provides a forecast for LivaNova PLC (LIVN) stock, including analyst price targets, historical stock performance, and expected earnings and revenue. It details the current stock price, market capitalization, and key financial metrics, while also addressing frequently
- Tone
- Positive 77/100
- Event
- Earnings
- Published
- 26 Jun 2026 13:43
- Source
- TradingView
LivaNova stock hits 52-week high at 81.08 USD By Investing.com
LivaNova PLC's stock reached a new 52-week high of $81.08, reflecting a 74% increase over the past year. The company's recent Q1 2026 earnings surpassed analyst expectations, and it has announced strategic leadership changes. InvestingPro analysis suggests the stock, currently tr
- Tone
- Positive 87/100
- Event
- Earnings
- Published
- 26 Jun 2026 12:39
- Source
- Investing.com South Africa